FundedPulseThe Pill vs. the Needle
If you have severe asthma or eczema, your treatment options are limited: expensive injectable biologics that can cost $30,000+ per year, require regular clinic visits, and come with needles. Korsana Biosciences is developing oral small molecules that target the same biological pathways — specifically STAT6, a key driver of allergic inflammation — but in pill form.
Their $175 million combined Seed/Series A gives them the runway to push their lead candidates into human clinical trials by the end of 2026. If they work, the impact could be enormous: making cutting-edge immunology treatments available at a fraction of the cost, without injections, and without clinic visits.
Why Investors Are Excited
The market for asthma and atopic dermatitis biologics is worth over $40 billion and growing fast. An oral alternative that matches their efficacy would be a blockbuster drug. Korsana's approach — targeting STAT6 with small molecules — represents one of the most promising mechanisms in modern immunology.